Boehringer Ingelheim Selects Medidata Clinical Cloud® to Accelerate Innovation in Drug Development


Company News Release

Medidata’s Cutting-Edge Technology Platform Will Enable Top-20 Global Pharma to
Conduct Faster, More Accurate and More Cost-Effective Clinical Trials
Selection of Medidata Underscores Boehringer Ingelheim’s Commitment to Deploy
Best-in-Class Technology to Power Groundbreaking Medical Advances
NEW YORK, N.Y.– December 21, 2015 – Medidata (NASDAQ: MDSO), the leading
global provider of cloud-based solutions for clinical research in life sciences, today
announced that Boehringer Ingelheim has selected the Medidata Clinical Cloud® to
accelerate innovation across all of its drug development programs. The top-20
global pharmaceutical company will leverage Medidata’s technology platform to
bring new insights and knowledge into multiple stages of the Boehringer Ingelheim
drug development process, enabling its researchers to conduct faster, more
accurate and more cost-effective clinical trials.
In supporting more than 10,000 clinical studies, 370,000 investigational sites and
more than 2.7 million trial volunteers, the Medidata platform is driving a
transformation in clinical trial design and execution, leading to better science and
new medical breakthroughs for patients. Leveraging the power of this platform,
Boehringer Ingelheim will integrate Medidata’s study planning, data management,
data analytics and risk-based monitoring (RBM) capabilities into multiple stages of
its drug development process.
“Boehringer Ingelheim creates therapeutic value through continuous innovation, so
fortifying our R&D efforts with smart, agile technology is vital to our continued
success,” said Klaus Stern, global head of Biostatistics & Data Sciences at
Boehringer Ingelheim. “Medidata’s platform of cloud-based solutions and data
analytics will increase the efficiency of our R&D and help us be more nimble in
developing and conducting increasingly complex clinical trials. Ultimately, this can
bring new medicines to patients sooner, which is what our team is working to do
every day.”
Named one of Reuters' top 100 global innovators in 2015, Boehringer Ingelheim
has deep therapeutic expertise in oncology, immunology and respiratory diseases,
cardiometabolic diseases, and diseases of the central nervous system. To enhance
its portfolio of Phase I-III and post-approval studies, Boehringer Ingelheim is
adopting the Medidata Clinical Cloud platform, including its solutions for electronic
data capture, management and reporting (Medidata Rave®); medical coding
(Medidata Coder®); safety reporting (Safety Gateway); trial design (Medidata
Designer®); and site budgeting and planning (Medidata Grants Manager®). The
Company will also use one of Medidata’s turnkey clinical analytics offerings
(Medidata Insights™), which provides advanced metrics, visualizations and the
most powerful set of industry data and benchmarks. A phased rollout will begin in
Additionally, Boehringer Ingelheim will utilize solutions within Medidata RBM
(including Medidata TSDV and Medidata SQM). These industry-leading tools for riskbased
monitoring (RBM) will allow Boehringer Ingelheim to better prioritize
resources around key areas of risk, such as patient safety and data quality and
integrity. Boehringer Ingelheim has long been a proponent of RBM as a member of
TransCelerate Biopharma, Inc. and as a representative within the non-profit’s riskbased
monitoring work stream.
“Boehringer Ingelheim is committed to a faster and more flexible approach to R&D,
and Medidata is excited to be a key partner in that effort for years to come,” said
Medidata’s chief executive officer Tarek Sherif. “Our cloud technology and datadriven
analytics deliver the features, the scale and the precise insights that
Boehringer Ingelheim and a rapidly growing list of other global pharma companies
need to develop exciting medical advances to improve people’s health and
transform their lives.”
Connect with Medidata
● Read our blog, Geeks Talk Clinical
● Tweet this: Top-20 global #pharma @Boehringer to power innovation in
#drugdevelopment through @Medidata #cloud #tech platform
● Follow us on Twitter: @Medidata
● Find us on LinkedIn
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates
globally with 146 affiliates and a total of more than 47,700 employees. The focus of
the family-owned company, founded in 1885, is researching, developing,
manufacturing and marketing new medications of high therapeutic value for human
and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer
Ingelheim. This includes worldwide involvement in social projects, such as the
initiative “Making more Health” and caring for the employees. Respect, equal
opportunities and reconciling career and family form the foundation of the mutual
cooperation. In everything it does, the company focuses on environmental
protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D
expenditure corresponds to 19.9 per cent of its net sales.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.